Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.

ABSTRACT:

Importance

Buprenorphine is an effective yet underused treatment for opioid use disorder (OUD).

Objective

To evaluate the feasibility (acceptability, tolerability, and safety) of 7-day injectable extended-release buprenorphine in patients with minimal to mild opioid withdrawal.

Design, setting, and participants

This nonrandomized trial comprising 4 emergency departments in the Northeast, mid-Atlantic, and Pacific geographic areas of the US included adults aged 18 years or older with moderate to severe OUD and Clinical Opiate Withdrawal Scale (COWS) scores less than 8 (minimal to mild), in which scores range from 0 to 7, with higher scores indicating increasing withdrawal. Exclusion criteria included methadone-positive urine, pregnancy, overdose, or required admission.

SUBMITTER: D'Onofrio G 

PROVIDER: S-EPMC11231806 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature